Literature DB >> 10618556

Rationale and design of the magnesium in coronaries (MAGIC) study: A clinical trial to reevaluate the efficacy of early administration of magnesium in acute myocardial infarction.

.   

Abstract

BACKGROUND: Mortality rate from ST-elevation myocardial infarction remains high in elderly patients and in patients who are not eligible for reperfusion therapy. Intravenous magnesium is a promising adjunctive treatment that may reduce reperfusion injury. Several earlier trials demonstrated a mortality rate reduction with magnesium treatment, but one large trial found no benefit. STUDY
DESIGN: Magnesium in Coronaries (MAGIC) is a large, simple trial designed to maximize the potential treatment effect of magnesium. 10, 400 high-risk patients with ST-elevation myocardial infarction will be randomly assigned to early treatment with intravenous magnesium sulfate or matching placebo. The primary end point is death at 30 days. Information on the need for treatment of shock and sustained ventricular arrhythmias will be collected to investigate the mechanisms by which magnesium might exert a beneficial effect. IMPLICATIONS: If magnesium proves beneficial, its use will provide a simple, cost-effective means to improve survival in this large patient population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618556

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  3 in total

1.  Treating acute myocardial infarction.

Authors:  W D Panton
Journal:  CMAJ       Date:  2001-02-06       Impact factor: 8.262

Review 2.  Drug treatment of elderly patients with acute myocardial infarction: practical recommendations.

Authors:  W S Aronow
Journal:  Drugs Aging       Date:  2001       Impact factor: 4.271

3.  Magnesium decreases cardiac injury in patients undergoing coronary artery bypass surgery.

Authors:  Adem Grbolar Resatoglu; Orhan Saim Demirturk; Nuran Yener; Ali Yener
Journal:  Ann Saudi Med       Date:  2004 Jul-Aug       Impact factor: 1.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.